Guangzhou Boyuan Outdoor Products Co., Ltd. is a modern enterprise located in Guangzhou, China, specializing in the research, development, and supply of high-purity peptide raw materials. Although the company name includes the word "Outdoor Products," Boyuan's core business is deeply rooted in the fields of biochemistry and laboratory research, and the company is dedicated to providing high-quality peptide products to research institutions, laboratories, and professional buyers worldwide. With years of industry experience, a strict quality control system, and an efficient global logistics network, Boyuan has rapidly developed into a trusted partner in the peptide raw material supply chain. The company's main products cover dozens of popular research peptides, including Semaglutide, Tirzepatide, Retatrutide, HCG, TB-500, GHK-CU, and many others, with specifications ranging from milligram to gram levels to meet the procurement needs of different scales. Boyuan always adheres to the business philosophy of "Quality First, Customer Supreme," and each batch of products is tested by High-Performance Liquid Chromatography (HPLC) to ensure purity of over 99%, with third-party test reports available upon customer request. In terms of warehousing and logistics, Boyuan has multiple warehouses within China and overseas, enabling rapid sorting and global shipping while supporting cold chain transport to ensure the stability of peptide products during transit. Whether for small batch purchases or bulk orders, Boyuan offers flexible and efficient solutions. Furthermore, Boyuan has a professional technical support and customer service team, providing product consultation, usage guidance, and after-sales follow-up, truly delivering a worry-free experience from order placement to receipt. Boyuan accepts various payment methods, including bank wire transfers, PayPal, credit cards, and cryptocurrencies in some regions, greatly facilitating transaction needs for customers from different countries. Based on market feedback, Boyuan's products have received high praise from customers, who generally agree that the products have stable purity, rapid reconstitution, good batch-to-batch consistency, and clear advantages in price compared to similar suppliers. Many customers specifically mention Boyuan's professionalism in packaging and logistics, noting that the cold chain packaging is robust with sufficient ice packs, ensuring the product remains in good lyophilized condition even after long-distance transportation. The company has established long-term and stable cooperative relationships with research institutions and distributors from countries such as the United States, Germany, the United Kingdom, Australia, Brazil, and South Korea. Boyuan will continue to develop in the peptide field, enriching its product line, improving quality control standards, optimizing its global logistics network, and actively exploring cooperation opportunities with research institutions. The company plans to introduce more novel peptide products in the future, including but not limited to research molecules such as MOTS-c, SS-31, and FOXO4, while further improving the product traceability system and customer service system. Boyuan believes that through continuous effort and innovation, it can provide global researchers with a better, more convenient, and more reliable experience in sourcing peptide raw materials.
Tirzepatide is a synthetic peptide consisting of 39 amino acids, and its chemical structure incorporates several key modifications that differentiate it from native GIP and GLP-1. One of the most important modifications is the attachment of a C20 fatty diacid moiety to the side chain of a lysine residue, which promotes strong binding to serum albumin and significantly extends the plasma half-life of Tirzepatide to approximately five days. This extended half-life supports once-weekly dosing in clinical research settings and makes Tirzepatide an excellent tool for long-term in vitro and in vivo studies. Additionally, the amino acid sequence of Tirzepatide incorporates specific substitutions that enhance its stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Unlike native GIP, which is rapidly degraded by DPP-4, Tirzepatide maintains high resistance to enzymatic cleavage, resulting in prolonged biological activity. These structural features collectively contribute to the superior pharmacokinetic profile of Tirzepatide, characterized by high bioavailability, sustained plasma concentrations, and predictable accumulation after repeated dosing. The physical properties of Tirzepatide include good solubility in DMSO and alkaline solutions, with a pH of approximately 5.0 to 6.5 when reconstituted at 1 milligram per milliliter in water. The lyophilized powder is white to off-white in appearance and forms a clear, colorless solution upon proper reconstitution with sterile water for research use, 0.9% saline, or sterile bacteriostatic water. Stability studies have shown that the lyophilized powder remains stable for at least 24 months at -20°C, for at least 12 months at 4°C, and for at least seven days at 25°C when protected from light. After reconstitution, the solution should be stored at 4°C and used within 24 to 48 hours, or aliquoted and frozen at -20°C for up to one month, with repeated freeze-thaw cycles strictly avoided.
The mechanism of action of Tirzepatide is fundamentally different from that of traditional GLP-1 monoagonists because it simultaneously activates both the GIP receptor and the GLP-1 receptor. This dual receptor agonism produces complementary and synergistic effects on glucose metabolism and body weight regulation. When Tirzepatide binds to GIP receptors on pancreatic beta cells, it activates intracellular cyclic adenosine monophosphate (cAMP) signaling pathways, leading to glucose-dependent insulin secretion. The term "glucose-dependent" means that insulin release is strongly stimulated only when blood glucose levels are elevated, and the effect is significantly reduced when blood glucose is normal, a characteristic that greatly lowers the risk of hypoglycemia. In addition to promoting insulin secretion, GIP receptor activation also supports beta cell survival and function by promoting beta cell proliferation and reducing apoptosis, which contributes to long-term pancreatic health. GIP also influences lipid metabolism in adipose tissue, promoting healthy fat distribution, and may positively influence bone formation through receptors present on osteoblasts. Meanwhile, activation of the GLP-1 receptor produces its own set of beneficial effects. GLP-1 potentiates insulin release from pancreatic beta cells in a glucose-dependent manner, inhibits glucagon secretion from pancreatic alpha cells to reduce hepatic glucose production, delays gastric emptying to reduce postprandial glucose spikes, and acts on GLP-1 receptors in the hypothalamus to increase satiety and reduce food intake. The combination of GIP and GLP-1 receptor activation produces effects that are greater than the sum of their individual contributions, resulting in superior glycemic control, more substantial and sustained body weight reduction, favorable changes in lipid profile, and a reduction in gastrointestinal side effects compared to what might be expected from single agonism alone.
Tirzepatide is widely used in various areas of metabolic research. In type 2 diabetes research, it serves as a valuable tool for studying the complementary roles of GIP and GLP-1 in glucose homeostasis, investigating glucose-dependent insulin secretion mechanisms, exploring beta cell preservation and regeneration, evaluating combination therapies for diabetes management, and advancing personalized medicine approaches based on incretin response profiles. In obesity and weight management research, the potent weight-reducing effects of Tirzepatide make it an excellent research tool for investigating central nervous system pathways that regulate appetite, studying energy expenditure and metabolic rate, researching body composition changes during weight loss, and evaluating long-term weight maintenance strategies. In metabolic syndrome research, Tirzepatide affects multiple components of metabolic syndrome, making it suitable for studies on dyslipidemia and lipid metabolism, hypertension and blood pressure regulation, insulin resistance and metabolic dysfunction, and inflammatory markers associated with metabolic disease. In cardiovascular research, preclinical studies suggest that GIP and GLP-1 receptor activation may have direct and indirect cardiovascular benefits, including improved endothelial function, reduced atherosclerosis progression, favorable cardiac remodeling, and reduced inflammatory pathways. In non-alcoholic fatty liver disease research, Tirzepatide has shown promise in reducing hepatic steatosis and improving liver enzymes, making it valuable for studies on hepatic lipid metabolism, fibrosis progression and regression, the gut-liver axis in metabolic disease, and combination therapies for NAFLD and NASH.
United States
Germany
Kenya
United Kingdom
Canada
Pls input... 
Pls input...